Request Demo
KSQ scores 'double-digit million' payment from Japan's Ono for preclinical cancer programs
25 Jan 2023
Cell TherapyImmunotherapyPhase 1License out/in
KSQ Therapeutics' deal with Ono Pharmaceutical comes almost exactly two years after a deal with Takeda worth up to $100 million to develop two T-cell programs as well a discovery program to identify NK cell targets.
KSQ Therapeuticssigning a coOno PharmaceuticalKSQ Therapeutics has garnered interest from anotheTakedanese pharma. This time it’s Ono Pharmaceutical, which is handing over a “double-digit million” upfront payment for a number of preclinical oncology programs.
The research-stage DNA damage responseTakeda pKSQ Therapeutics identified using KSQ’s CRISPRomics platform technology. In return, Ono Pharmaceuticalsachusetts-based biotech will be eligible for milestone payments that could stretch into the “triple-digit millions” as well as royalties, the company said.
“This acquisition of multiple research-stage oncology programs by Ono is further validation of the power of our platform to identify novel oncology targets and develop potential first-in-class programs,” KSQ CEO Qasim Rizvi. "This is an important transaction for KSQ, enabling us to focus on our other programs. We look forward to watching Ono’s progress as they advance these programs toward clinical studies."
The aim of KSQ’s CRISPRomics platform is to decodKSQ-4279nomeUSP1 inhibitorUSP1identify potential gene targets for oncology and autoimmune disease therapies. As well as KSQ-4279, the biotech has used the platform tPARPrk on a pair of preclinical T-cell therapies, while a Treg program remains in the discovery stages.
The Ono traKSQction comes almost exactly two years after a deal with Takeda worth up to $100 million to develop twautoimmune diseaseas well a discovery proKSQ-4279identify natural killer cell targets. However, KSQ had been quiet on the collaboration since then.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.